MicuRx is dedicated to creating treatments for patients with infections caused by multidrug-resistant super bacteria. Beyond that, MicuRx also has a pipeline of other investigational medicines for cancer and inflammation.
Contezolid (MRX-I) MRX-I
1、Next generation oxazolidinone antibiotic designed and developed by MicuRx
2、Target multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus,vancomycin-resistant Enterococci, penicillin-resistant Streptococcus pneumoniae, etc
3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 11th, 12th, 13th five-year period
4、Global Multi-Center Phase III trial initiated (MRX-4 sequential Contezolid)
MRX-4 MRX-4
1、Injectable new oxazolidinone antibiotics designed and developed by MicuRx
2、Target multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus,vancomycin-resistant Enterococci, penicillin-resistant Streptococcus pneumoniae, etc
3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 13th five-year period
4、Global Multi-Center Phase III trial initiated (MRX-4 sequential Contezolid)
MRX-8 MRX-8
1、Next generation polymyxin antibiotic designed and developed by MicuRx
2、Target multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Klebsiella pneumoniae, etc
3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 13th five-year period
MRX-5 MRX-5
1、Novel boron compound designed and developed by MicuRx
2、Target multidrug resistant Gram-negative bacteria
MRX-17 MRX-17
1、Novel kidney-targeted treatment designed and developed by MicuRx
2、To achieve superior efficacy and safety by increasing the local concentration of active drug via renal-targeted delivery
MRX-23 MRX-23
A next-generation monoclonal antibody drug conjugate (ADC) targeting tumors
Featuring a new generation of camptothecin toxin and an optimized linker
MRX-15 MRX-15
1、Novel kidney-targeted treatment designed and developed by MicuRx
2、To achieve superior efficacy and safety by increasing the local concentration of drug via renal-targeted delivery